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Abstract
Aims: A sub-population of cells named cancer stem cells (CSCs) that initiate and promote tumour growth have 
been demonstrated to exist in several malignancies including colon carcinoma. The objective of our pilot study 
was to isolate CD133+CD26+CD44+ CSCs from patient colon tumours, culture spheres or organoids and observe 
their proliferation in primary cultures. Parallel cultures of non-cancer controls from colon normal lining and non-
adenomatous polyps were set up. 
Methods: Magnetic activated cell sorting was used to isolate CD133+CD26+CD44+ cell populations followed 
by primary cell culturing under stem cell culture conditions. Number, cells/organoid and daughter generations of 
organoids were calculated using phase contrast microscope. Trypan blue exclusion method was used to test the 
viability of the cells.
Results: Both colon tumour and colon non-adenomatous polyp formed floating organoids in suspension; however 
non-adenomatous polyp cultures did not show self-renewal properties for more than 1 passage. Normal colon single-
cell suspension did not create organoids. Metastatic colon tumours rapidly produce cancer cell organoids in less 
than 24 hours in larger numbers compared to non-metastatic colon tumours (1-3 weeks). Metastatic colon tumour 
organoids have the ability for proliferation for upto five daughter generations in primary culture compared to three 
generations for those grown from non-metastatic tumours. 
Conclusions: This in vitro CSC organoid model will help study colon cancer biology, in particular providing a 
valuable source of primary cell-derived tissue for studying personalized molecular profiling using ‘omics strategies 
to direct therapeutic intervention.
Keywords: Colon cancer; Primary culture; Cancer cell sphere; 
Cancer stem cells; In vitro assay
Statement 
This study was performed on primary cultures of fresh site-
specific colon tissues to generate in vitro cancer cell organoid models. 
As opposed to current literature, we cultured non-cancer colon and 
compared proliferation patterns to that of tumor tissues and observed 
differences. This study established a model for in vitro colon tissue 
generation to study colorectal disease progression.
Introduction
Colorectal cancer (CRC) is the 3rd most common cancer type 
worldwide and the 4th most common cause of cancer-related mortality 
with almost 694,000 people dying annually [1]. According to GloboCan 
2012 estimates, colorectal malignancies constituted 10.0% and 9.2% 
of all cancer cases in men and women, respectively. More than half 
of these cases occurred in developed countries where mortality was 
substantially lower than the incidence rate. However, more CRC 
related deaths (52% in 2012) occurred in countries scoring low on the 
development index, reflecting relative poor survival in these regions 
[2]. It has been estimated that there were 95,270 new cases of colon 
cancer diagnosed in USA and 90% to 92% of patients were treated 
surgically [3-5]. Colorectal cancer incidence and death rates declined 
by approximately 3% per year in both men and women from 2003-
2012, with momentum gained in the most recent years likely driven 
by the increased uptake of colonoscopy screening [5]. In Asia, the 
incidence of colorectal carcinoma is similar but lower than found in the 
developed countries. The risk of developing the disease is alike in both 
sexes at present, however a 41% rise in incidence was noted in the males 
between 1995-1999 [6]. In a single-center retrospective study of adult 
patients with colon cancer diagnosed through 2000-2003 (93 patients; 
M: F=1.58: 1, mean age of diagnosis 54 years), 49.5% of the patients 
had right sided (mortality rate 51.6%), 10.8% had transverse colon 
(mortality rate 37.5%), 7.5% had descending colon (mortality rate 
66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers [7]. 
At Shaukat Khanum Memorial Cancer Hospital and Research Centre 
(SKMCH&RC, Pakistan), CRCs were among the top five malignancies 
(3530 cases, 4.91%) diagnosed amongst all age-groups, both sexes 
combined registered from 1994 to 2015.
Poor survival rate is in part attributed to limited understanding 
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of the characteristics of resistant cancer cells which are now termed 
cancer stem cells (CSCs) or tumour initiating cells (TICs). The evidence 
for the existence of CSCs has been reported in blood borne cancer 
(CD34+CD38-) [8], in solid tumour including breast (CD44+CD24-) 
[9,10], brain (CD133+) [11], prostate (CD44+) [12] and pancreatic 
(CD44+CD24+ESA+) [13]. The first report on colon cancer stem cells 
showed that tumourigenic cells were contained within in the rare 
undifferentiated population that express CD133 [14]. A surface marker 
profile for isolated CRC stem cells was reported to be epithelial cell 
adhesion molecule (EpCAM)high/CD44+/CD166+ [15]. Identification 
of CD133+CD26+CD44+ colorectal CSC is a relatively recent report. 
A study of 43 patient tumours (27 without liver metastasis, 5 with 
synchronous liver metastasis on presentation and 15 metachronous 
liver metastases) analyzed the expression of these markers in dissociated 
tumour cells by three-color flow cytometry [16]. The most important 
finding of this study is the ability of CD26+ cells to cause liver metastasis 
when injected into the cecum of mice irrespective of CD133 or CD44 
expression. However, co-expression of CD133 and CD44 did increase 
the tumourigenic capacity of CD26+ cells. Transient transfection of 
CD26 siRNA decreased migratory and invasive capacities of the CD26+ 
CSCs suggesting that CD26 plays a functional role in the invasive 
capacity of CD26+ CSCs.
CD44 is overexpressed in colon cancers, which often have hyper-
activation of the WNT signaling pathway. Deletion of the WNT target, 
CD44, in Apc(Min/+) mice attenuated intestinal tumourigenesis [17]. 
CD44, a class I transmembrane glycoprotein that binds to hyaluronan, 
with various roles from adhesion to signaling [18], is known as a 
marker of tumour aggressiveness playing a functional role in metastasis 
[19] and is also a promising marker of CSCs [20]. However, CD44 
expression is not limited to CSCs, as many non-CSCs can also express 
CD44. Hence, combination of CD44 with other markers is used to 
identify potential CSCs [21]. CD44 expression has been associated with 
poor patient survival in multiple cancer types, including colon cancers 
[18]. In intestinal stem cells and in transit-amplifying cells distinct 
CD44 isoforms contribute to tumour formation [22].
CD133 is a five-transmembrane glycoprotein and identified as a 
marker of neural CSCs and normal primitive cells of the hematopoietic, 
epithelial and endothelial lineages [23-25]. Interestingly, CD133+ cells 
from colon tumours have stem-like properties and grow exponentially 
in vitro as undifferentiated tumour organoids. In colon cancer, they 
account for approximately 2.5% of the tumour cells [14] and can 
initiate tumour growth in immune-deficient mice [26]. Recent findings 
indicated CD133+ cells comprised of both stem-like and differentiated 
progenitor cells suggesting the CD133+ sub-population (with a 
combination marker) had multi-functional roles. Co-expression of 
epithelial cell adhesion molecule (EpCam) and CD44+ in CD133+ 
fraction further differentiates a sub-group which possess tumourigenic 
properties [15]. 
CD26 or Dipeptidyl-peptidase IV (DPPIV) is a serine peptidase 
involved in cell differentiation, adhesion, immune modulation and 
apoptosis, all functions which control neoplastic transformation, and 
its’ up-regulation was observed in colorectal tumours [27]. An anti-
migratory and invasive effect was found with ATP-competitive pan 
Raf265 inhibitor treatment in combination with 5FU by targeting 
CD26+ CRC cells [28]. 
In the present study, we used primary colon tissues to isolate CSC 
and characterize cultured organoids. 
Materials and Methods
All chemicals were obtained from Sigma-Aldrich unless stated 
otherwise.
Patient specimen collection 
A total of 22 colon specimen were obtained (following consent) from 
patients, undergoing screening colonoscopy and/or invasive surgery 
from 2015-2016, at SKMCH&RC, Pakistan. Ethical approval of the 
study was obtained from the Internal Review Board on Human Research 
at SKMCH&RC. Specimens of normal colonic mucosa and colon non-
adenomatous polyp biopsies (2 mm3 to 5 mm3), to be used as non-
cancer controls, were collected from non-cancer patients undergoing 
screening colonoscopy. Specimens were collected within 30 minutes of 
resection and placed in RMPI medium with 5x antibiotic (500 µg/mL 
streptomycin, 500 Units penicillin and 1.25 µg/mL amphotericin-B) 
immediately. A part of the tissue was fixed in formalin for embedding 
into paraffin wax (for histo-pathological diagnosis) and the remaining 
tissue was either processed for isolation of cells or stored at -80°C in 1x 
phosphate-buffered saline (PBS). Colon tumour tissues were obtained 
during laparoscopy or open surgery performed for tumour resection. 
These specimens were collected and processed as described above. The 
manifestation of normal, hyperplastic or neoplastic cells in the attained 
specimen was confirmed by two independent histo-pathologists. The 
clinic-pathological features of patients are summarized in Table 1.
Single-cell suspension formation from colon tissues
Mucus containing samples were incubated in sputolysin reagent 
(100 mM PBS (pH 7.0), 6.5 mM Dithiothreitol) for 15 minutes at 
room temperature and rinsed with Hank’s balanced salt solution 
(HBSS). A single-cell suspension of each biopsy was generated using 
the method of Pang et al. [16]. Briefly, fresh specimens were washed 
with 1xPBS, minced on ice and transferred to 15 mL centrifuge tube 
containing Dulbecco’s Modified eagles Medium (DMEM), combination 
of Hyaluronidase (Calbiochem, Heidelberg, USA) and Collagenase 
IV (Invitrogen, Paisley, UK) for enzymatic disaggregation. Complete 
digestion was ensured by stirring the mixture every 15 minutes 
and incubation at 37°C for up to 3 hours. The cellular debris in the 
resulting single-cell suspension was filtered using 40 µm nylon mesh 
and washed twice with HBSS/2% Hank’s buffered salt solution in heat 
inactivated calf serum (HICS). Histopaque-1077 centrifugation as per 
the manufacturer’s instructions was used to remove red blood cells.
Magnetic bead affinity cell sorting (MACS) of 
CD133+CD26+CD44+
From the resulting single-cell suspension, CD133+CD26+CD44+ 
were isolated using a Miltenyi Biotech kit as per the manufacturer’s 
instructions. Briefly, single-cell suspensions were incubated with 
a monoclonal CD133-APC (Miltenyi Biotech, Bergisch Gladbach, 
Germany) antibody, labeled with MicroBeads (Miltenyi Biotech) for 
30 min at 4°C. Anti-APC Multisort Kit (Miltenyi Biotech) was used to 
obtain the CD133+ cells followed by cleavage from the MicroBeads using 
release reagent from the kit. CD133+ cells were incubated with CD26-
PE (Miltenyi Biotech) antibody and Anti-PE Multisort Kit (Miltenyi 
Biotech) was used to obtain CD133+CD26+ cells. The microbeads were 
cleaved from the CD133+CD26+ cells by using the release reagent in the 
Multisort kit. The CD133+CD26+ cells were incubated with the CD44 
Microbeads (Miltenyi Biotech,) to obtain CD133+CD26+CD44+ cells. 
The filtrate was collected containing CD44-CD26-CD133- cells.
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Primary culture of CD133+CD26+CD44+ cell organoids
Separate cultures for each type of fresh specimen (colon normal 
lining, colon non-adenomatous polyp and colon tumour) were set up. 
The resulting single-cells (CD133+CD26+CD44+) were passed 
through a 40 μm filter and placed in stem cell conditions (non-
adherent stem cell medium; DMEM/F12, 1 × antibiotic/antimycotic 
mixture, 0.4% bovine serum albumin (BSA), 1% glutamine, insulin 5 
μg/mL, 20 ng/mL epidermal growth factor (EGF) (Invitrogen), 10 ng/
mL basic fibroblast growth factor (bFGF) [Invitrogen]) without feeder 
cells (fibroblasts or amniotic membrane) to test their ability for forming 
organoids containing CSCs. Non-adherent stem cell medium (10 mL) 
containing 1 × 103 cells were cultured in ultra-low attachment 25 mm2 
culture flasks (Corning Inc., Corning, NY) (29). The culture flasks were 
placed at 37°C, 85% humidity and 5% CO2 replacing fresh medium 
once/week. When floating organoids were formed, they were collected 
by centrifugation. Parallel cultures under adherent condition (10% 
BSA, 1% glutamine, no EGF and bFGF) were set up in collagen-coated 
culture flasks. The filtrate containing CD44-CD26-CD133- cells was also 
cultured both in adherent and non-adherent conditions (1 × antibiotic/
antimycotic mixture, 10% bovine serum albumin, 1% glutamine, no 
EGF and bFGF) in collagen-coated culture flasks. 
Self-renewal assay
The organoids, collected by centrifugation and digested to single-
cell suspension using Dispase II (20 U/mL of DMEM), were filtered 
through 40 μm filter. For daughter organoids formation and colony 
formation, 250 cells/cm2 in 10 mL of medium were cultured in non-
adherent or adherent 25 cm2 culture flasks, respectively. The organoids 
in suspension and adhesive colonies were observed using phase contrast 
microscope (Labomed TCM 400). Trypan blue exclusion method was 
used to test the viability of the cells.
Results
Organoid formation in primary cultures of 
CD133+CD26+CD44+ Cells
The single-cell suspension from each type of colon normal lining 
(Figure 1a), colon non-adenomatous polyp (Figure 1d) and colon 
tumour (Figure 1g and 1j) was incubated in non-adherent stem cell 
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Figure 1: Representative phase contrast images of spheres (arrows) formed in suspension in primary cultures of colon tissues (f, i, l) in growth factor supplemented 
medium in non-adhesive ultra-low attachment flasks; Panel 1: Colon normal lining (Non-cancer) (a-c): (a) trypsin-digested single-cell suspension, (b) isolated 
CD133+CD26+CD44+ cells cultured under stem cell conditions, (c) No spheres formed within 3 weeks and cells started to differentiate onwards. Panel 2: Colon non-
adenomatous polyp (Non-cancer) (d-f): (d) trypsin-digested single-cell suspension, (e) isolated CD133+CD26+CD44+ cells cultured under stem cell conditions, (f) 
created and survived for 3 weeks. One generation of secondary spheres were formed. Panel 3: Colon tumour (Non-Metastatic) (g-i): (g) trypsin-digested single-
cell suspension, (h) isolated CD133+CD26+CD44+ cells cultured under stem cell conditions, (i) created within 24 hours and survived for several. Re-passaged for 3 
generations. Panel 4: Colon tumour (Metastatic) (j-l): (j) trypsin-digested single-cell suspension, (k) isolated CD133+CD26+CD44+ cells cultured under stem cell 
conditions, (l) created within 24 hours and survived for several. Re-passaged for 5 generations. Magnification 20x.
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medium to observe their organoid formation patterns in primary cell 
culture. Purified CD133+CD26+CD44+ cells exhibited sphere-forming 
abilities compared to the CD133-CD26-CD44- equivalents. The MACS 
isolated cells (Figure 1b) from non-cancer colon normal lining did 
not produce characteristic compact round organoids (Figure 1c). 
The isolated CD133+CD26+CD44+ cells (Figure 1e) from colon non-
adenomatous polyp showed a slow growth pattern of loosely compact 
organoids (Figure 1f) which did not survive for more than a month. 
However, organoids (which mimic tumor in a flask) were generated at 
much faster rate within 1 day from CD133+CD26+CD44+ cells isolated 
from non-metastatic (Stage II) tumours (Figure 1i) organoids, whereas 
those isolated from advanced disease metastatic (Stage IV) tumours 
(Figure 1l) exhibited highest growth rate and cell numbers in less than 
24 hours. After 24 hours of culture, floating undifferentiated CD44-
CD26-CD133- cells start to adhere to the flask (both collagen coated and 
non-coated) and attain the shape similar to that of colon epithelial cells. 
Self-renewal of cancer cell organoids
The ability for self-renewal and adoption of a spherical 
morphology, attributed to the presence of CSCs, were tested by 
collecting the CD133+CD26+CD44+ cell organoids and culturing them 
after dissociation into single-cells. The secondary organoids were 
formed within 1 week from colon non-adenomatous tissue but did not 
regenerate secondary organoids on 2nd passage. A progressive loss of 
regenerative ability by the third passage was observed with primary 
cells from non-metastatic tumours and by fifth passage for those from 
metastatic cancers (Table 2).
Discussion
The aim of our pilot study was to isolate CD133+CD26+CD44+ CSCs 
from patient colon tumours, culture spheres or organoids and observe 
their proliferation in primary cultures. We setup primary cultures 
from human colon tumour to grow cancer cell organoids, isolated 
CD133+CD26+CD44+ cells by MACS followed by culturing to produce 
cell organoids. Normal tissues were processed as the tumor tissues 
using same method of isolation. Under the same culture conditions, 
the non-cancer cells did not produce organoids while those from non-
metastatic and metastatic tumours produced compact, round and 
multi-cellular organoids (Figure 1) confirming that only tumour cells 
have self-renewal abilities. The non-cancer tissue produced single-cells 
which died after few weeks of culture. The organoids from different 
tissue sources, survived over different time periods (1-30 days), which 
could be attributed to the different type of cells with specific set of 
mutated genes in various tissues (Table 2). 
Comprehensive comparisons of gene pool and proteome of these 
organoids from various stages of cancer can be helpful in monitoring 
CRC progression and metastasis. These genetic and proteomic 
differences between non-adenomatous polyps and normal colon lining, 
which did not translate into identifiable histologic features, could be the 
reason why non-adenomatous polyps demonstrated a loosely compact 
sphere formation pattern (Figure 1f) absent from normal colon lining 
cultures. This organoid model may provide the means for in-depth 
‘omics’ analyses to understand the dynamics of the cancer.
Conclusion
In summary, we successfully isolated CD133+CD26+CD44+ cells 
from human colon tissues by magnetic beads and generated colon 
cancer cell organoids in primary cultures in supplemented medium. The 
potential applications for colon organoids (potentially harboring CSCs) 
characterization include developing methods for CSC detection, CSC 
resistance to cancer therapies, identifying new potential therapeutic 
targets and study mechanism of suppression of cancer metastasis.
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